Broad Sarbecovirus Neutralization by Combined Memory B Cell Antibodies to Ancestral SARS-CoV-2

Overview

Journal iScience

Publisher Cell Press

Date 2024 Jul 29

PMID 39071888

Authors

Cyril Planchais

Ignacio Fernandez

Benjamin Chalopin

Timothee Bruel

Pierre Rosenbaum

Maxime Beretta

Jordan D Dimitrov

Laurine Conquet

Flora Donati

Matthieu Prot

Francoise Porrot

Delphine Planas

Isabelle Staropoli

Florence Guivel-Benhassine

Eduard Baquero

Sylvie van der Werf

Ahmed Haouz

Etienne Simon-Loriere

Xavier Montagutelli

Bernard Maillere

Felix A Rey

Pablo Guardado-Calvo

Herve Nozach

Olivier Schwartz

Hugo Mouquet

Affiliations

Soon will be listed here.

Abstract

Antibodies play a pivotal role in protecting from SARS-CoV-2 infection, but their efficacy is challenged by the continuous emergence of viral variants. In this study, we describe two broadly neutralizing antibodies cloned from the memory B cells of a single convalescent individual after infection with ancestral SARS-CoV-2. Cv2.3194, a resilient class 1 anti-RBD antibody, remains active against Omicron sub-variants up to BA.2.86. Cv2.3132, a near pan-Sarbecovirus neutralizer, targets the heptad repeat 2 membrane proximal region. When combined, Cv2.3194 and Cv2.3132 form a complementary SARS-CoV-2 neutralizing antibody cocktail exhibiting a local dose-dependent synergy. Thus, remarkably robust neutralizing memory B cell antibodies elicited in response to ancestral SARS-CoV-2 infection can withstand viral evolution and immune escape. The cooperative effect of such antibody combination may confer a certain level of protection against the latest SARS-CoV-2 variants.

Citing Articles

Structural Immunology of SARS-CoV-2.

Yuan M, Wilson I Immunol Rev. 2024; 329(1):e13431.

PMID: 39731211 PMC: 11727448. DOI: 10.1111/imr.13431.

References

Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M . LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022; 39(7):110812. PMC: 9035363. DOI: 10.1016/j.celrep.2022.110812. View

Barouch D . Covid-19 Vaccines - Immunity, Variants, Boosters. N Engl J Med. 2022; 387(11):1011-1020. PMC: 9454645. DOI: 10.1056/NEJMra2206573. View

Elshabrawy H, Coughlin M, Baker S, Prabhakar B . Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012; 7(11):e50366. PMC: 3503966. DOI: 10.1371/journal.pone.0050366. View

Krissinel E, Henrick K . Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007; 372(3):774-97. DOI: 10.1016/j.jmb.2007.05.022. View

Ianevski A, Giri A, Aittokallio T . SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022; 50(W1):W739-W743. PMC: 9252834. DOI: 10.1093/nar/gkac382. View

Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C . Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021; 595(7867):426-431. PMC: 8277577. DOI: 10.1038/s41586-021-03696-9. View

Zhang J, Xiao T, Cai Y, Chen B . Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021; 50:173-182. PMC: 8423807. DOI: 10.1016/j.coviro.2021.08.010. View

Williams C, Headd J, Moriarty N, Prisant M, Videau L, Deis L . MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2017; 27(1):293-315. PMC: 5734394. DOI: 10.1002/pro.3330. View

Low J, Jerak J, Tortorici M, McCallum M, Pinto D, Cassotta A . ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science. 2022; 377(6607):735-742. PMC: 9348755. DOI: 10.1126/science.abq2679. View

10.

Roemer C, Sheward D, Hisner R, Gueli F, Sakaguchi H, Frohberg N . SARS-CoV-2 evolution in the Omicron era. Nat Microbiol. 2023; 8(11):1952-1959. DOI: 10.1038/s41564-023-01504-w. View

11.

Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P . Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2022; 23(3):189-199. PMC: 9514166. DOI: 10.1038/s41577-022-00784-3. View

12.

Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View

13.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

14.

Muecksch F, Weisblum Y, Barnes C, Schmidt F, Schaefer-Babajew D, Wang Z . Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021; 54(8):1853-1868.e7. PMC: 8323339. DOI: 10.1016/j.immuni.2021.07.008. View

15.

Corti D, Purcell L, Snell G, Veesler D . Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021; 184(12):3086-3108. PMC: 8152891. DOI: 10.1016/j.cell.2021.05.005. View

16.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View

17.

Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K . Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670. PMC: 9531318. DOI: 10.1038/s41586-021-04386-2. View

18.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

19.

Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M . Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024; 15(1):2254. PMC: 10938001. DOI: 10.1038/s41467-024-46490-7. View

20.

Witte L, Baharani V, Schmidt F, Wang Z, Cho A, Raspe R . Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. Nat Commun. 2023; 14(1):302. PMC: 9849103. DOI: 10.1038/s41467-023-35927-0. View